Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

Moderna MRNA incurred a loss of $2.50 per share in the fourth quarter of 2024, narrower than the Zacks Consensus Estimate of ...

A trial of Moderna’s norovirus vaccine in the U.S. has been put on hold by the FDA over a reported case of neurological ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

Overall vaccine sales declined by 4% in 2024. Shingrix, GSK’s shingles vaccine, saw a modest 1% increase in sales, while ...

Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

GSK has today posted a better-than-expected fourth quarter and lifted its 2031 sales target to nearly $50 billion as the ...